Most recently, Patrick Holt served as president of Cordis, Cardinal Health’s global interventional cardiovascular business and a member of Cardinal Health Inc's operating committee. Cordis, with revenue of ca.$1B, 3,800 associates, is a worldwide leader in the research, development, manufacture, and commercialization of medical technology. Cordis has a 60-year heritage of partnership with the physician community, to treat millions of patients.Holt was responsible for the Cordis enterprise globally until its successful divestment to Hellman and Friedman in August 2021, for an enterprise value of $1.012B. This represented the 9th largest MedTech M&A transaction in 2021. He brought to the role more than 20 years of leadership experience across all aspects of end-to-end commercialization in the life sciences industry, specifically medical technology and biopharmaceuticals, including vaccines. Holt’s tenure was underscored by the successful enterprise-wide turnaround of Cordis. Realizing this outcome was founded on a return to revenue growth, a refocused R&D strategy, as well as a significant and sustained enhancements in operational effectiveness.In conjunction with this, Holt led a long-term strategic review of Cordis, which resulted in the recommendation to separate the division from Cardinal Health. Holt led the successful transaction process.Previously, Holt served as president of the Cardinal Health in Asia-Pacific. He led the integration and expansion of the company's portfolio, which included Cordis and the patient recovery businesses acquired from Medtronic.Previously, Holt held leadership positions of increasing responsibility at Allergan Inc., including vice president and regional managing director of Asia, focused in therapeutic areas such as medical aesthetics, ophthalmology, neurology, and urology. Prior, he served as vice president and managing director for key markets including Greater China, Japan, and South Korea. Before joining Allergan Inc., Holt spent over a decade at Merck & Co Inc. [known as MSD outside North America], where he held a series of leadership positions in Australia, South Korea, and Indonesia, across numerous therapeutic areas in biopharmaceuticals and vaccines. Holt is a non-executive director and audit committee member of Hugel Inc., [145020.KQ], a publicly listed global biopharmaceutical company and a non-executive director of Ascenda Loyalty, a global technology company that makes banking rewarding.He earned a bachelor’s degree in biochemistry and chemistry from Monash University, Australia.